{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:43:26Z","timestamp":1777952606364,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06327-9","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T07:28:32Z","timestamp":1743233312000},"page":"3035-3046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["First-line treatment of TAFRO syndrome with rituximab: a case report and literature review"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7892-6603","authenticated-orcid":false,"given":"Salar","family":"Servati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-0329","authenticated-orcid":false,"given":"Ida","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6511-4103","authenticated-orcid":false,"given":"Shahryar","family":"Rajai Firouzabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"4","key":"6327_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/MOH.0b013e328186ffab","volume":"14","author":"A Dham","year":"2007","unstructured":"Dham A, Peterson BA (2007) Castleman disease. Curr Opin Hematol 14(4):354\u2013359","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"6327_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.hoc.2017.09.004","volume":"32","author":"D Wu","year":"2018","unstructured":"Wu D, Lim MS, Jaffe ES (2018) Pathology of Castleman disease. Hematology\/Oncology Clin 32(1):37\u201352","journal-title":"Hematology\/Oncology Clin"},{"key":"6327_CR3","doi-asserted-by":"crossref","unstructured":"Shahidi H, Myers JL, Kvale PA (1995) Castleman\u2019s Disease Mayo Clin Proc 70(10):969\u2013977","DOI":"10.4065\/70.10.969"},{"key":"6327_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1749-8090-4-31","volume":"4","author":"CH Chen","year":"2009","unstructured":"Chen CH et al (2009) Possible roles of Epstein-Barr virus in Castleman disease. J Cardiothorac Surg 4:31","journal-title":"J Cardiothorac Surg"},{"issue":"5","key":"6327_CR5","first-page":"320","volume":"51","author":"K Takai","year":"2010","unstructured":"Takai K et al (2010) [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, Ascites and hepatosplenomegaly]. Rinsho Ketsueki 51(5):320\u2013325","journal-title":"Rinsho Ketsueki"},{"issue":"2","key":"6327_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2169\/internalmedicine.55.4710","volume":"55","author":"Y Yamaga","year":"2016","unstructured":"Yamaga Y et al (2016) Successful treatment with cyclosporin A in Tocilizumab-resistant TAFRO syndrome. Intern Med 55(2):185\u2013190","journal-title":"Intern Med"},{"issue":"3","key":"6327_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3109\/14397595.2015.1120389","volume":"28","author":"K Sakai","year":"2018","unstructured":"Sakai K et al (2018) TAFRO syndrome successfully treated with Tocilizumab: A case report and systematic review. Mod Rheumatol 28(3):564\u2013569","journal-title":"Mod Rheumatol"},{"issue":"6","key":"6327_CR8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12185-016-1978-2","volume":"103","author":"S Fujiwara","year":"2016","unstructured":"Fujiwara S et al (2016) Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol 103(6):718\u2013723","journal-title":"Int J Hematol"},{"issue":"1","key":"6327_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2162-3619-4-3","volume":"4","author":"S Tedesco","year":"2015","unstructured":"Tedesco S et al (2015) Successful treatment of a Caucasian case of multifocal Castleman\u2019s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol 4(1):3","journal-title":"Exp Hematol Oncol"},{"key":"6327_CR10","doi-asserted-by":"crossref","unstructured":"Gagnier JJ et al (2013) The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep, 2013","DOI":"10.1136\/bcr-2013-201554"},{"key":"6327_CR11","unstructured":"Review Manager Review Manager 5 (RevMan 5), The Cochrane Collaboration: Copenhagen"},{"issue":"10","key":"6327_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.crad.2017.05.007","volume":"72","author":"T Kiguchi","year":"2017","unstructured":"Kiguchi T et al (2017) CT findings in 11 patients with TAFRO syndrome: a variant of multicentric Castleman\u2019s disease. Clin Radiol 72(10):905.e1-905.e5","journal-title":"Clin Radiol"},{"issue":"1","key":"6327_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","volume":"111","author":"Y Masaki","year":"2020","unstructured":"Masaki Y et al (2020) 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111(1):155\u2013158","journal-title":"Int J Hematol"},{"key":"6327_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5414\/CNCS109400","volume":"6","author":"Y Noda","year":"2018","unstructured":"Noda Y et al (2018) Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage. Clin Nephrol Case Stud 6:16\u201320","journal-title":"Clin Nephrol Case Stud"},{"key":"6327_CR15","doi-asserted-by":"crossref","unstructured":"Minamikawa S et al (2020) A pediatric case of tocilizumab-resistant TAFRO syndrome treated successfully with rituximab, vol 67. Pediatric Blood & Cancer, 12","DOI":"10.1002\/pbc.28489"},{"issue":"10","key":"6327_CR16","doi-asserted-by":"publisher","first-page":"11255","DOI":"10.3390\/cimb46100668","volume":"46","author":"T Kakutani","year":"2024","unstructured":"Kakutani T, Kamada R, Tamai Y (2024) Pathophysiology, treatment, and prognosis of thrombocytopenia, Anasarca, fever, reticulin fibrosis\/renal failure, and organomegaly (TAFRO) syndrome: A review. Curr Issues Mol Biol 46(10):11255\u201311269","journal-title":"Curr Issues Mol Biol"},{"issue":"11","key":"6327_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ajh.24015","volume":"90","author":"P Jain","year":"2015","unstructured":"Jain P et al (2015) Durable remission with rituximab in a patient with an unusual variant of Castleman\u2019s disease with myelofibrosis-TAFRO syndrome. Am J Hematol 90(11):1091\u20131092","journal-title":"Am J Hematol"},{"issue":"3","key":"6327_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/bjh.17868","volume":"196","author":"L Maisonobe","year":"2022","unstructured":"Maisonobe L et al (2022) Characteristics of thrombocytopenia, Anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort. Br J Haematol 196(3):599\u2013605","journal-title":"Br J Haematol"},{"key":"6327_CR19","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer A-L et al (2023) Crosstalk in the diseased plasma cell niche \u2013 the force of inflammation. Front Immunol 14:1120398","DOI":"10.3389\/fimmu.2023.1120398"},{"issue":"1","key":"6327_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hoc.2017.09.001","volume":"32","author":"D Simpson","year":"2018","unstructured":"Simpson D (2018) Epidemiology of Castleman disease. Hematol Oncol Clin North Am 32(1):1\u201310","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"6327_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/PAP.0b013e3181a9d4d3","volume":"16","author":"DM Cronin","year":"2009","unstructured":"Cronin DM, Warnke RA (2009) Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 16(4):236\u2013246","journal-title":"Adv Anat Pathol"},{"issue":"21","key":"6327_CR22","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1182\/blood.V120.21.4253.4253","volume":"120","author":"M Mehra","year":"2012","unstructured":"Mehra M et al (2012) Use of a claims database to characterize and estimate the incidence of Castleman\u2019s disease. Blood 120(21):4253","journal-title":"Blood"},{"key":"6327_CR23","doi-asserted-by":"crossref","unstructured":"Akagi Y et al (2021) Intracranial hemorrhage in a patient with TAFRO syndrome treated with cyclosporine A and rituximab. Medicina-Lithuania, 57(9)","DOI":"10.3390\/medicina57090971"},{"issue":"23","key":"6327_CR24","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.2169\/internalmedicine.8360-16","volume":"56","author":"T Aoki","year":"2017","unstructured":"Aoki T et al (2017) Tocilizumab-resistant TAFRO syndrome complicated by type II respiratory failure. Intern Med 56(23):3249\u20133254","journal-title":"Intern Med"},{"key":"6327_CR25","doi-asserted-by":"publisher","first-page":"e919536","DOI":"10.12659\/AJCR.919536","volume":"21","author":"G Ducoux","year":"2020","unstructured":"Ducoux G et al (2020) Thrombocytopenia, Anasarca, fever, reticulin fibrosis\/renal failure, and organomegaly (TAFRO) syndrome with bilateral adrenal hemorrhage in two Caucasian patients. Am J Case Rep 21:e919536","journal-title":"Am J Case Rep"},{"issue":"6","key":"6327_CR26","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s12328-021-01515-2","volume":"14","author":"M Hayashi","year":"2021","unstructured":"Hayashi M et al (2021) TAFRO syndrome complicated by porto-sinusoidal vascular liver disease with portal hypertension: a case report. Clin J Gastroenterol 14(6):1711\u20131717","journal-title":"Clin J Gastroenterol"},{"issue":"1","key":"6327_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2177\/jsci.39.64","volume":"39","author":"S Hiramatsu","year":"2016","unstructured":"Hiramatsu S et al (2016) Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi 39(1):64\u201371","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"6327_CR28","first-page":"1","volume":"10","author":"T Hou","year":"2017","unstructured":"Hou T et al (2017) TAFRO syndrome: A case report and review of the literature. Hum Pathology: Case Rep 10:1\u20134","journal-title":"Hum Pathology: Case Rep"},{"issue":"4","key":"6327_CR29","first-page":"252","volume":"12","author":"Z \u0130slamo\u011flu","year":"2018","unstructured":"\u0130slamo\u011flu Z et al (2018) Tafro syndrome: A case report from Turkey and review of the literature. Int J Hematology-Oncology Stem Cell Res 12(4):252\u2013258","journal-title":"Int J Hematology-Oncology Stem Cell Res"},{"key":"6327_CR30","doi-asserted-by":"crossref","unstructured":"Jos\u00e9 FF et al (2017) A life-threatening case of TAFRO syndrome with dramatic response to Tocilizumab, rituximab, and pulse steroids: the first case report in Latin America. Med (United States), 96(13)","DOI":"10.1097\/MD.0000000000006271"},{"issue":"48","key":"6327_CR31","first-page":"E32200","volume":"101","author":"T Kakutani","year":"2022","unstructured":"Kakutani T et al (2022) Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, Anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report. Med (United States) 101(48):E32200","journal-title":"Med (United States)"},{"issue":"4","key":"6327_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1620\/tjem.236.289","volume":"236","author":"Y Konishi","year":"2015","unstructured":"Konishi Y et al (2015) Successful treatment of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, with cyclosporine A: possible pathogenetic contribution of Interleukin-2. Tohoku J Exp Med 236(4):289\u2013295","journal-title":"Tohoku J Exp Med"},{"issue":"12","key":"6327_CR33","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/ccr3.2502","volume":"7","author":"ZY Li","year":"2019","unstructured":"Li ZY et al (2019) Multicentric Castleman disease with TAFRO syndrome and Sj\u00f6gren\u2019s. Clin Case Rep 7(12):2388\u20132392","journal-title":"Clin Case Rep"},{"key":"6327_CR34","doi-asserted-by":"crossref","unstructured":"Louis C et al (2017) TAFRO syndrome in Caucasians: A case report and review of the literature. Front Med 4:149","DOI":"10.3389\/fmed.2017.00149"},{"issue":"2","key":"6327_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.revmed.2020.10.384","volume":"42","author":"J Maquet","year":"2021","unstructured":"Maquet J et al (2021) TAFRO syndrome and cutaneous necrotizing vasculitis. Rev Med Interne 42(2):134\u2013139","journal-title":"Rev Med Interne"},{"issue":"4","key":"6327_CR36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/ejh.13473","volume":"105","author":"M Marchetti","year":"2020","unstructured":"Marchetti M, Feyles E, Zinzani P (2020) Frontline Siltuximab and rituximab in TAFRO syndrome: A case report. Eur J Haematol 105(4):505\u2013507","journal-title":"Eur J Haematol"},{"issue":"6","key":"6327_CR37","first-page":"e4946","volume":"11","author":"JL Miatech","year":"2019","unstructured":"Miatech JL et al (2019) TAFRO syndrome: A case of significant endocrinopathy in a Caucasian patient. Cureus 11(6):e4946","journal-title":"Cureus"},{"issue":"8","key":"6327_CR38","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ekir.2020.05.004","volume":"5","author":"H Mizuno","year":"2020","unstructured":"Mizuno H et al (2020) The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep 5(8):1172\u20131179","journal-title":"Kidney Int Rep"},{"issue":"3","key":"6327_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000492743","volume":"141","author":"K Morita","year":"2019","unstructured":"Morita K et al (2019) TAFRO syndrome with an anterior mediastinal mass and lethal Autoantibody-Mediated thrombocytopenia: an autopsy case report. Acta Haematol 141(3):158\u2013163","journal-title":"Acta Haematol"},{"issue":"10","key":"6327_CR40","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2169\/internalmedicine.56.7991","volume":"56","author":"M Nara","year":"2017","unstructured":"Nara M et al (2017) Two cases of thrombocytopenia, Anasarca, fever, reticulin fibrosis\/renal failure, and organomegaly (TAFRO) syndrome with high serum procalcitonin levels, including the first case complicated with adrenal hemorrhaging. Intern Med 56(10):1247\u20131252","journal-title":"Intern Med"},{"issue":"12","key":"6327_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.14740\/jmc3784","volume":"12","author":"Y Otsuka","year":"2021","unstructured":"Otsuka Y et al (2021) Successful treatment of thrombocytopenia, Anasarca, fever, reticulin myelofibrosis\/renal insufficiency, and organomegaly syndrome using plasma exchange followed by rituximab in the intensive care unit. J Med Cases 12(12):474\u2013480","journal-title":"J Med Cases"},{"key":"6327_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.humpath.2018.04.011","volume":"82","author":"A Shinozaki-Ushiku","year":"2018","unstructured":"Shinozaki-Ushiku A et al (2018) Glomeruloid hemangioma associated with TAFRO syndrome. Hum Pathol 82:172\u2013176","journal-title":"Hum Pathol"},{"key":"6327_CR43","doi-asserted-by":"crossref","unstructured":"Shah N et al (2022) To and TAFRO - a cryptic cause of acute renal failure: a case report. BMC Nephrol, 23(1)","DOI":"10.1186\/s12882-022-02660-7"},{"key":"6327_CR44","doi-asserted-by":"crossref","unstructured":"Simeni Njonnou SR et al (2020) Unexplained cause of thrombocytopenia, fever, Anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology. BMJ Case Rep, 13(6)","DOI":"10.1136\/bcr-2019-234155"},{"key":"6327_CR45","first-page":"p4703608","volume":"2016","author":"M Simons","year":"2016","unstructured":"Simons M et al (2016) TAFRO syndrome associated with EBV and successful triple therapy treatment: case report and review of the literature. Case Rep Hematol 2016:p4703608","journal-title":"Case Rep Hematol"},{"issue":"10","key":"6327_CR46","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2169\/internalmedicine.0116-17","volume":"57","author":"H Tsurumi","year":"2018","unstructured":"Tsurumi H et al (2018) Remission of refractory Ascites and discontinuation of Hemodialysis after additional rituximab to Long-term glucocorticoid therapy in a patient with TAFRO syndrome. Intern Med 57(10):1433\u20131438","journal-title":"Intern Med"},{"key":"6327_CR47","doi-asserted-by":"publisher","first-page":"e926721","DOI":"10.12659\/AJCR.926721","volume":"21","author":"M Wada","year":"2020","unstructured":"Wada M et al (2020) An autopsy case of TAFRO syndrome with type II respiratory failure. Am J Case Rep 21:e926721","journal-title":"Am J Case Rep"},{"issue":"1","key":"6327_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/24725625.2020.1789304","volume":"5","author":"R Wakiya","year":"2021","unstructured":"Wakiya R et al (2021) Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab. Mod Rheumatol Case Rep 5(1):145\u2013151","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"6327_CR49","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/mrcr\/rxad020","volume":"7","author":"M Watanabe","year":"2023","unstructured":"Watanabe M et al (2023) Combined B-cell Immunomodulation with rituximab and Belimumab in severe, refractory TAFRO syndrome associated with Sj\u00f6gren\u2019s syndrome: A case report. Mod Rheumatol Case Rep 7(2):475\u2013479","journal-title":"Mod Rheumatol Case Rep"},{"key":"6327_CR50","doi-asserted-by":"crossref","unstructured":"Wu X et al (2023) The experience of diagnosis and treatment for TAFRO syndrome. Ann Hematol","DOI":"10.1007\/s00277-023-05435-8"},{"issue":"4","key":"6327_CR51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12185-016-2025-z","volume":"104","author":"S Yasuda","year":"2016","unstructured":"Yasuda S et al (2016) Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy. Int J Hematol 104(4):512\u2013518","journal-title":"Int J Hematol"},{"key":"6327_CR52","doi-asserted-by":"crossref","unstructured":"Zhou QY et al (2020) Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature. BMC Nephrol, 21(1)","DOI":"10.1186\/s12882-020-02119-7"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06327-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:57Z","timestamp":1749105477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06327-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6327"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06327-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was waived by the relevant institutional ethics committee of Shahid Beheshti University of Medical Sciences. All procedures are in accordance with the ethical standards as laid down in the 1964 declaration of Helsinki and the institutional research committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Verbal informed consent was attained by the treating physician (S.S.) from the patient. All imagery of the patient has been anonymized and patient consent regarding publication was provided by the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}